

Fibrinolysis influences SARS-CoV-2 infection in ciliated cells

Yapeng Hou¹, Yan Ding¹, Hongguang Nie^{1, *}, Hong-Long Ji²

¹Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Liaoning 110122, China. ²Department of Cellular and Molecular Biology, University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA.

*Address correspondence to hgnie@cmu.edu.cn

Abstract

Rapid spread of COVID-19 has caused an unprecedented pandemic worldwide, and an inserted furin site in SARS-CoV-2 spike protein (S) may account for increased transmissibility. Plasmin, and other host proteases, may cleave the furin site of SARS-CoV-2 S protein and γ subunits of epithelial sodium channels (γ ENaC), resulting in an increment in virus infectivity and channel activity. As for the importance of ENaC in the regulation of airway surface and alveolar fluid homeostasis, whether SARS-CoV-2 will share and strengthen the cleavage network with ENaC proteins at the single-cell level is urgently worthy of consideration. To address this issue, we analyzed single-cell RNA sequence (scRNA-seq) datasets, and found the PLAU (encoding urokinase plasminogen activator), SCNN1G (γ ENaC), and ACE2 (SARS-CoV-2 receptor) were co-expressed in alveolar epithelial, basal, club, and ciliated epithelial cells. The relative expression level of PLAU, TMPRSS2, and ACE2 were significantly upregulated in severe COVID-19 patients and SARS-CoV-2 infected cell lines using Seurat and DESeq2 R packages. Moreover, the increments in PLAU, FURIN, TMPRSS2, and ACE2 were predominately observed in different epithelial cells and leukocytes. Accordingly, SARS-CoV-2 may share and strengthen the ENaC fibrinolytic proteases network in ACE2 positive airway and alveolar epithelial cells, which may expedite virus infusion into the susceptible cells and bring about ENaC associated edematous respiratory condition.

Keywords: SARS-CoV-2; plasmin; ENaC; COVID-19; furin

29 Introduction

30 The SARS-CoV-2 infection leads to COVID-19 with pathogenesis and clinical features similar to those
31 of SARS and shares the same receptor, angiotensin-converting enzyme 2 (ACE2), with SARS-CoV to enter
32 host cells (Zhou et al. 2020, Li and Zheng 2020). By comparison, the transmission ability of SARS-CoV-2 is
33 much stronger than that of SARS-CoV, owing to diverse affinity to ACE2 (Wrapp and Wang 2020). The
34 fusion capacity of coronavirus *via* the spike protein (S protein) determines infectivity (Wrapp and Wang 2020,
35 Kam et al. 2009b). Highly virulent avian and human influenza viruses bearing a furin site (RxxR) in the
36 haemagglutinin have been described (Coutard et al. 2020). Cleavage of the furin site enhances the entry ability
37 of Ebola, HIV, and influenza viruses into host cells (Claas et al. 1998). Consisting of receptor-binding (S1)
38 and fusion domains (S2), coronavirus S protein needs to be primed through the cleavage at S1/S2 site and S2'
39 site for membrane fusion (Jaimes et al. 2020, Huggins 2020). The newly inserted furin site in SARS-CoV-2 S
40 protein significantly facilitated the membrane fusion, leading to enhanced virulence and infectivity (Xia et al.
41 2020, Wang, Qiu, et al. 2020).

42 Plasmin cleaves the furin site in SARS-CoV S protein (Kam et al. 2009b), which is upregulated in the
43 vulnerable populations of COVID-19 (Ji et al. 2020). However, whether plasmin cleaves the newly inserted
44 furin site in the SARS-CoV-2 S protein remains obscure. Plasmin cleaves the furin site of human γ subunit of
45 epithelial sodium channels (γ ENaC) as demonstrated by LC-MS and functional assays (Zhao, Ali, and Nie
46 2020, Sheng et al. 2006). Very recently, it has been proposed that the global pandemic of COVID-19 may
47 partially be driven by the targeted mimicry of ENaC α subunit by SARS-CoV-2 (Gentzsch and Rossier 2020,
48 Muhanna et al. 2020). ENaC are located at the apical side of the airway and alveolar cells, acting as a critical
49 system to maintain the homeostasis of airway surface and alveolar fluid homeostasis (Ji et al. 2006, Matalon,
50 Bartoszewski, and Collawn 2015). The luminal fluid is required for keeping normal ciliary beating to expel
51 inhaled pathogens, allergens, and pollutants and for migration of immune cells that release pro-inflammatory
52 cytokines and chemokines (Hou et al. 2019a). The plasmin family and ACE2 are expressed in the respiratory
53 epithelium (Nie et al. 2009, Hanukoglu and Hanukoglu 2016, Kam et al. 2009a). However, if the plasmin
54 system and ENaC are involved in the fusion of SARS-CoV-2 into host cells is unknown.

55 This study aims to determine whether PLAU, SCNN1G, and ACE2 are co-expressed in the airway and
56 lung epithelial cells and whether SARS-CoV-2 infection alters their expression at the single-cell level. We
57 found that these genes, especially the PLAU was significantly upregulated in epithelial cells of
58 severe/moderate COVID-19 patients and SARS-CoV-2 infected cell lines, mainly owing to ciliated cells. We
59 conclude that the most susceptible cells for SARS-CoV-2 infection could be the ones co-expressing these
60 genes and sharing plasmin-mediated cleavage.

61

62 **Results**

63 **Furin sites are identified in both virus and host γ ENaC proteins**

64 A furin site was located at the S proteins of SARS-CoV-2 from Arginine-683 to Serine-687 (RRAR|S),
65 and similar site was also seen in the S protein of HCoV-OC43, MERS, and HCoV-HKU1 coronavirus (**Fig.**
66 **1A**). In addition, the highly conserved RxxR motif existed in the hemagglutinin protein of influenza H3N2,
67 Herpes, Ebola, HIV, Dengue, hepatitis B, West Nile, Marburg, Zika, Epstein-Barr, and respiratory syncytial
68 virus (RSV). The furin site (RKRR|E) was found in the gating relief of inhibition by proteolysis (GRIP)
69 domain of the extracellular loop of the mouse, rat, and human γ ENaC (**Fig. 1B**). The similarity of these furin
70 sites is 40-80%.

71 **Respiratory cells co-express PLAU, SCNN1G, and ACE2**

72 To identify subpopulations of cells co-expressing PLAU, SCNN1G, and ACE2, we analyzed 11 scRNA-
73 seq datasets by nferX scRNA-seq platform (<https://academia.nferx.com/>) (**Supplementary Table 1**). All three
74 genes were co-expressed in the following cells ranked by the expression level of PLAU from high to low: club
75 cells, goblets, basal cells, AT1 cells, ciliated cells, fibroblasts, mucous cells, deuterosomal cells, and AT2 cells
76 (**Fig. 1C**), which were supported by previous studies (Sungnak et al. 2020, Wang et al. 2008, Hanukoglu and
77 Hanukoglu 2016). These results suggest that these cell populations co-expressing PLAU- γ ENaC-ACE2 may
78 be more susceptible to the SARS-CoV-2 infection compared with others. In addition, the top ten ranked cell
79 sub-populations expressing PLAU, SCNN1G, or ACE2 alone were listed in **Supplementary Table 2**. To
80 compare the transcript of the proteases in different lung epithelial cells, we analyzed the lung dataset from
81 Gene Expression Omnibus (GEO) by Seurat, and the cells were annotated by their specific markers
82 (**Supplementary Fig. 1A**). The data showed that all these proteases were expressed in AT2 cells, including
83 PLAU, FURIN, PRSS3 (Trypsin), ELANE (Elastase), PRTN3 (Myeloblastin), CELA1 (Elastase-1), CELA2A
84 (Elastase-2A), CTRC (Chymotrypsin-C), TMPRSS4 (Transmembrane protease serine 4), and TMPRSS2
85 (Transmembrane protease serine 2) (**Supplementary Fig. 1B**). In AT2 cells, the proteases expression level in
86 order is: TMPRSS2 > FURIN > TMPRSS4 > PLAU > CELA1 > ELANE > PRSS3 > PRTN3 > CTRC >
87 CLEA2A. For PLAU, the high to low order is Basal > Club > Ciliated > AT1 > AT2.

88 The expression levels of proteases (PLAU, FURIN, TMPRSS2, PLG), ACE2, and SCNN1G in 11 cell
89 types co-expressing ACE2, SCNN1G, and PLAU were compared in **Fig. 2**. The club cells showed the highest
90 expression level of PLAU, and the ACE2, SCNN1G, TMPRSS2, FURIN, and PLG showed a higher
91 expression level in club cells compared with other cell types. Of note, the ciliated cell was the second and
92 seventh highest expression cell type of PLAU and ACE2, respectively.

93 Expression levels of PLAU, SCNN1G, and ACE2 in SARS-CoV-2 infection

94 To detect the potential changes in the cell populations that co-express PLAU, SCNN1G, and ACE2, we
95 analyzed the scRNA-seq datasets of bronchoalveolar lavage fluid (BALF) cells, which are mainly composed
96 of epithelial cells and leukocytes. There were three groups to be studied: 4 healthy controls, 3 moderate, and
97 6 severe COVID-19 patients. The expression level and the percentage of total cells expressing PLAU and
98 FURIN were significantly upregulated in the severe group compared with controls ($P < 0.001$), as well as the
99 expression levels of ACE2, TMPRSS2, SCNN1G, and PLG were also slightly upregulated (**Fig. 3A and B**).

100 The expression levels of PLAU, Furin, TMPRSS2, and ACE2 and the number of cells were profiled in
101 **Fig. 4A**. The data showed that these genes were upregulated in COVID-19 patients, and the number of cells
102 expressing these upregulated genes almost increased in a severity-dependent manner. PLAU was significantly
103 elevated in severe group ($P < 0.001$), and the other genes also showed an increasing trend (**Fig. 4B**).

104 The increments in PLAU (alveolar epithelial cells, basal, and ciliated cells), PLG (basal cells), FURIN
105 (alveolar epithelial cells, basal, ciliated cells), TMPRSS2 (basal and ciliated cells), SCNN1G (alveolar
106 epithelial cells and basal cells), and ACE2 (alveolar epithelial cells, basal, and club) were predominately
107 observed in different cells. Especially, a significant increase in PLAU expression was seen in ciliated cells,
108 while the expression of measured genes showed a decline in COVID-19 goblets (**Fig. 4C**). In addition, similar
109 changes of these genes in leukocytes were shown in **Supplementary Fig. 2**.

110 To incorporate the results in COVID-19 patients, we analyzed bulk-seq data of 3 human respiratory
111 epithelial cell lines infected with SARS-CoV-2: A549, Calu-3, and NHBE (Blanco-Melo et al. 2020). PLAU
112 transcript was significantly upregulated in all three cell lines after SARS-CoV-2 infection (multiplicity of
113 infection = 2) (**Fig. 5**, $P < 0.001$). However, TMPRSS2 was only upregulated in infected Calu-3 cells,
114 evidenced by recent studies ($P < 0.001$) (Xu et al. 2020). Similar to those of SARS and MERS, the SARS-
115 CoV-2 infection also increased the expression level of ACE2 in A549 cells ($P < 0.05$) (Smith et al. 2020).
116 Although SARS-CoV-2 did not change the mRNA level of SCNN1G significantly in these cell lines as that
117 for influenza virus, researchers are warned to pay more attention to the post-translational modification
118 of γ ENaC (Hou et al. 2019b).

120 Discussion

121 The novel coronavirus, SARS-CoV-2, was identified as the causative agent for a series of atypical
122 respiratory diseases, and the disease termed COVID-19 was officially declared a pandemic by the World
123 Health Organization on March 11, 2020 (Pollard, Morran, and Nestor-Kalinoski 2020). SARS-CoV-2 has a
124 great impact on human health all over the world, the virulence and pathogenicity of which may be relevant to

125 the inserted furin site. Whilst the SARS-CoV-2 S2' cleavage site has a similar sequence motif to SARS-CoV
126 and would thus be suitable for cleavage by trypsin-like proteases, insertions of additional arginine residues at
127 the SARS-CoV-2 S1/S2 (RRAR|S) clearly generate a furin cleavage site (Zhou et al. 2020). Interestingly, this
128 difference has been implicated in the viral transmissibility of SARS-CoV-2 (Anand et al. 2020). Our data
129 supported the investigation that furin sites (RRAR|S) not only exist in human virus but also in the γ -subunit
130 of ENaC, which expresses highly in alveolar epithelial cells and a substrate to be cleaved by plasmin.

131 Plasmin has also been reported to have the ability to cleavage the furin site, and enhance the virulence
132 and pathogenicity of viruses in their envelope proteins (Sidarta-Oliveira et al. 2020). SARS-CoV-2 has
133 evolved a unique S1/S2 cleavage site, absent in any previous coronavirus sequenced, resulting in the striking
134 mimicry of an identical furin-cleavable peptide on α ENaC, a protein critical for the homeostasis of airway
135 surface liquid (Anand et al. 2020). All the above indicates that SARS-CoV-2 infection will hijack the ENaC
136 proteolytic network, which is associated with the edematous respiratory condition (**Fig. 6**) (Chen et al. 2014,
137 Zhao, Ali, and Nie 2020). Our data showed that the respiratory cells co-express SARS-CoV-2 receptor, γ ENaC
138 (SCNN1G), and plasmin family mainly belonged to alveolar type I/II, basal, club, and ciliated cells,
139 respectively. The PLG (Plasminogen) expression in different cell types is not shown for its expression is too
140 low to be detected in many lung scRNA-seq datasets. Of note, the ciliated cell is the predominant contributor
141 to upregulate the PLAU gene in severe COVID-19 patients. As expected, PLAU levels, as well as TMPRSS2,
142 are upregulated in respiratory epithelial cell lines after SARS-CoV-2 infection, supporting the idea that SARS-
143 CoV-2 can facilitate ACE2-mediated viral entry *via* TMPRSS2 spike glycoprotein priming (Roberts et al.
144 2020). Enhanced PLAU expression induced by SARS-CoV-2 infection will activate the plasminogen, which
145 may reduce the difficulty of SARS-CoV-2 invasion by cleaving the S protein.

146 The scRNA-seq data of bronchoalveolar lavage fluid cells from COVID-19 patients do not show the
147 expression difference of SCNN1G (γ ENaC), which is considered to be regulated by plasmin through
148 proteolytic hydrolysis. ENaC activity is not only determined by mRNA/protein expression but also cell
149 proteases. Once the ENaC is biosynthesized and trafficked to the Golgi, it is likely to be modified by
150 intracellular protease (furin). After inserted into plasma membrane, ENaC will encounter the opportunity for
151 full proteolytic activation of the channel by extracellular proteases (elastase, plasmin, chymotrypsin, and
152 trypsin) (Thibodeau and Butterworth 2013). Intriguingly, the PLG gene also did not show a difference between
153 COVID-19 patients and healthy control, indicating that hyperfibrinolysis in COVID-19 patients may be
154 induced by enhanced urokinase (Ji et al. 2020). Additional analysis of clinical studies or animal models is
155 urgently needed to future explore the relationship between the plasmin, ENaC, and SARS-CoV-2 receptors at
156 the protein level.

157 The amplified incidence of thrombotic events had been previously reported on COVID-19, and tissue

plasminogen activator (tPA) was tried to treat stroke in COVID-19 patients (Vinayagam and Sattu 2020). We did not analyze the changes of PLAT in BALF cells of COVID-19 patients due to the tPA (PLAT) is generally expressed in endothelial cells. Similarly, the beneficial effects of plasmin on alveolar fluid clearance and novel mechanisms underlying the cleavage of human ENaCs at multiple sites by plasmin have been provided in our recent studies (Zhao, Ali, and Nie 2020). New drugs that regulate the uPA/ uPA receptor (uPAR) system have been demonstrated to help treat the severe complications of pandemic COVID-19 (D'Alonzo, De Fenza, and Pavone 2020). Amiloride, a prototypic inhibitor of ENaC, can be an ideal candidate for COVID-19 patients, supporting that ENaC is a downstream target of plasmin and involved in the luminal fluid absorption in SARS-CoV-2 infection (Adil, Narayanan, and Somanath 2020). Considering the two diametrically different therapeutic regimes in practice to address the complicated coagulopathic changes in COVID-19, fibrinolytic (alteplase, tPA) (Bona et al. 2020, Ly et al. 2020, Wang, Hajizadeh, et al. 2020, Barrett et al. 2020, Christie et al. 2020, Papamichalis et al. 2020, Poor et al. 2020, Arachchillage et al. 2020) and antifibrinolytic therapies (nafamostat and tranexamic acid) (Asakura and Ogawa 2020, Doi et al. 2020, Thierry 2020), our data provide new and comprehensive information on fibrinolytic related therapy targeting plasmin(ogen) as a promising approach to combat COVID-19.

Methods

Alignment of furin sites in viral and γ ENaC proteins

The sequences of γ ENaC proteins (rat, mouse, and humans) and human viruses were acquired from the UniProt (<https://www.uniprot.org/>). The accession numbers were P0DTC2 (for SARS-CoV-2), P04578 (HIV), P03435 (H3N2), A0A3G2XEB3 (Ebola), A0A140AYZ5 (MERS), P03188 (Epstein-Barr), P04488 (Herpes), P17763 (Dengue), P26662 (hepatitis), Q9Q6P4 (West Nile), A0A024B7W1 (Zika), P03420 (respiratory syncytial virus), P35253 (Marburg), P36334 (HCoV-OC43), A0A140H1H1 (HCoV-HKU1), P51170 (human γ ENaC), Q9WU39 (mouse γ ENaC), and P37091 (rat γ ENaC). Alignment was performed using the JalView software (Version: 2.11.1.0). The 3D structure of SARS-CoV-2 S (PDB ID: 6X2A) and γ ENaC (PDB ID: 6BQN) was modified and downloaded from the Protein Data Bank (<http://www.rcsb.org/>).

Co-expression profiles of γ ENaC, ACE2, and proteases

We performed a systematic expression profiling of ACE2 and γ ENaC across 11 published human single-cell RNA sequence (scRNA-seq) studies comprising ~0.4 million cells using the nferX Single-Cell platform (<https://academia.nferx.com/>) (Anand et al. 2020). The mean expression of PLAU, SCNN1G, and ACE2 in a given cell-population (mean CP10k) was Z-score normalized (to ensure the Standard deviation = 1 and mean ~ 0 for all the genes) to obtain relative expression profiles across all the samples. The expression of PLAU,

190 SCNN1G, and ACE2 in the respiratory system were analyzed and graphed as heatmaps using R package
191 *pheatmap*.

192 **Acquisition, filtering, and processing of scRNA-seq data**

193 The dataset downloaded from the Gene Expression Omnibus was filtered for integration. Lung scRNA-
194 seq dataset (8 healthy controls in GSE122960) were filtered by total number of reads ($nreads > 1,000$), number
195 of detected genes ($50 < ngenes < 7,500$), and mitochondrial percentage ($mito.pc < 0.2$). BALF scRNA-seq
196 dataset was composed of 3 healthy controls, 3 moderate and 6 severe COVID-19 patients in GSE145926, and
197 1 healthy control in GSM3660650. These datasets were filtered by total number of reads ($nreads > 1,000$),
198 number of detected genes ($20 < ngenes < 6,000$), and mitochondrial percentage ($mito.pc < 0.1$). Finally, a
199 filtered gene-barcode matrix of all samples was integrated with the Seurat v3 to remove batch effects across
200 different donors as described previously (Stuart et al. 2019).

201 **Dimensionality reduction and clustering**

202 The filtered gene-barcode matrix was first normalized using the ‘LogNormalize’ methods in Seurat v.3
203 with default parameters. The top 2,000 variable genes were then identified using the ‘vst’ method in Seurat
204 FindVariableFeatures function. Principal Component Analysis (PCA) was performed using the top 2,000
205 variable genes. Then Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP) or
206 t-Distributed Stochastic Neighbor Embedding (tSNE) was performed on the top 50 principal components for
207 visualizing the epithelial cells. Meanwhile, the graph-based clustering was performed on the PCA-reduced
208 data for clustering analysis with Seurat v.3. The resolution was set to 0.6 and 0.15 for the lung and BALF
209 datasets to obtain a finer result, respectively. The markers used for BALF cell annotation were shown by the
210 bubble plot in **Supplementary Fig. 3**.

211 **Differentiation of gene expression levels**

212 Differentiation of gene expression level in BALF cells among the healthy, moderate, and severe groups
213 was achieved using the Wilcox in Seurat v.3 (FindMarkers function). Then, we divided BALF cells into
214 epithelial cells and leukocytes and compared gene expression levels among their subgroups. Both epithelial
215 and leukocytes were re-clustered to detect the differences in gene expression of all cell types between healthy
216 controls and severe/moderate COVID-19 patients. Bulk-seq data (GSE147507) was analyzed for the
217 differential genes in respiratory epithelial cell lines using the DESeq2 with Wald test and Benjamini-Hochberg
218 post-hoc test (Blanco-Melo et al. 2020, Love, Huber, and Anders 2014). It was considered significant if $P <$
219 0.05.

221 **Acknowledgment**

222 This study was supported by NSFC 81670010, NIH grants HL87017, HL095435, and HL134828, AHA
223 Awards AHA14GRNT20130034 and AHA16GRNT30780002. We were grateful to Yunlai Zhou (Yangzhou
224 University) and Congxi Zhang (Gene denovo) for their assistance on bioinformatics.

225

226 **Conflict of interest**

227 The authors declare no conflicts of interest.

228

229

230 References

- 231 Adil, M. S., S. P. Narayanan, and P. R. Somanath. 2020. "Is amiloride a promising cardiovascular medication to persist in the
232 COVID-19 crisis?" *Drug Discov Ther* no. 14 (5):256-258. doi: 10.5582/ddt.2020.03070.
- 233 Anand, P., A. Puranik, M. Aravamudan, and A. J. Venkatakrishnan. 2020. "SARS-CoV-2 strategically mimics proteolytic activation
234 of human ENaC." *Elife* no. 9:e58603. doi: 10.7554/eLife.58603.
- 235 Arachchillage, D. J., A. Stacey, F. Akor, M. Scotz, and M. Laffan. 2020. "Thrombolysis restores perfusion in COVID-19 hypoxia."
236 no. 190 (5):e270-e274. doi: 10.1111/bjh.17050.
- 237 Asakura, H., and H. Ogawa. 2020. "Potential of heparin and nafamostat combination therapy for COVID-19." *J Thromb Haemost*
238 no. 18 (6):1521-1522. doi: 10.1111/jth.14858.
- 239 Barrett, C. D., A. Oren-Grinberg, E. Chao, A. H. Moraco, M. J. Martin, S. H. Reddy, A. M. Ilg, R. Jhunjunwala, M. Uribe, H. B.
240 Moore, E. E. Moore, E. N. Baedorf-Kassis, M. L. Krajewski, D. S. Talmor, S. Shaefi, and M. B. Yaffe. 2020. "Rescue
241 therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case
242 series." *J Trauma Acute Care Surg* no. 89 (3):453-457. doi: 10.1097/ta.0000000000002786.
- 243 Blanco-Melo, D., B. E. Nilsson-Payant, W. C. Liu, S. Uhl, D. Hoagland, R. Moller, T. X. Jordan, K. Oishi, M. Panis, D. Sachs, T.
244 T. Wang, R. E. Schwartz, J. K. Lim, R. A. Albrecht, and B. R. tenOever. 2020. "Imbalanced Host Response to SARS-CoV-
245 2 Drives Development of COVID-19." *Cell* no. 181 (5):1036-1045 e9. doi: 10.1016/j.cell.2020.04.026.
- 246 Bona, R. D., A. Valbusa, G. Malfa, D. R. Giacobbe, P. Ameri, N. Patroniti, C. Robba, V. Gilad, A. Insoresi, M. Bassetti, P. Pelosi, and
247 I. Porto. 2020. "Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in
248 severe COVID-19: a case series." *Eur Heart J Cardiovasc Pharmacother*. doi: 10.1093/ehjcvp/pvaa087.
- 249 Chen, Z., R. Zhao, M. Zhao, X. Liang, D. Bhattarai, R. Dhiman, S. Shetty, S. Idell, and H. L. Ji. 2014. "Regulation of epithelial
250 sodium channels in urokinase plasminogen activator deficiency." *Am J Physiol Lung Cell Mol Physiol* no. 307 (8):L609-
251 17. doi: 10.1152/ajplung.00126.2014.
- 252 Christie, D. B., 3rd, H. M. Nemece, A. M. Scott, J. T. Buchanan, C. M. Franklin, A. Ahmed, M. S. Khan, C. W. Callender, E. A.
253 James, A. B. Christie, and D. W. Ashley. 2020. "Early outcomes with utilization of tissue plasminogen activator in COVID-
254 19-associated respiratory distress: A series of five cases." *J Trauma Acute Care Surg* no. 89 (3):448-452. doi:
255 10.1097/ta.0000000000002787.
- 256 Claas, E. C., A. D. Osterhaus, R. van Beek, J. C. De Jong, G. F. Rimmelzwaan, D. A. Senne, S. Krauss, K. F. Shortridge, and R. G.
257 Webster. 1998. "Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus." *Lancet* no. 351
258 (9101):472-7. doi: 10.1016/s0140-6736(97)11212-0.
- 259 Coutard, B., C. Valle, X. de Lamballerie, B. Canard, N. G. Seidah, and E. Decroly. 2020. "The spike glycoprotein of the new
260 coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade." *Antiviral Res* no. 176:104742.
261 doi: 10.1016/j.antiviral.2020.104742.
- 262 D'Alonzo, D., M. De Fenza, and V. Pavone. 2020. "COVID-19 and pneumonia: a role for the uPA/uPAR system." *Drug Discov*
263 *Today* no. 25 (8):1528-1534. doi: 10.1016/j.drudis.2020.06.013.
- 264 Doi, K., M. Ikeda, N. Hayase, K. Moriya, and N. Morimura. 2020. "Nafamostat mesylate treatment in combination with favipiravir
265 for patients critically ill with Covid-19: a case series." *Crit Care* no. 24 (1):392. doi: 10.1186/s13054-020-03078-z.
- 266 Gentzsch, M., and B. C. Rossier. 2020. "A Pathophysiological Model for COVID-19: Critical Importance of Transepithelial Sodium
267 Transport upon Airway Infection." *Function (Oxf)* no. 1 (2):zqaa024. doi: 10.1093/function/zqaa024.
- 268 Hanukoglu, I., and A. Hanukoglu. 2016. "Epithelial sodium channel (ENaC) family: Phylogeny, structure-function, tissue
269 distribution, and associated inherited diseases." *Gene* no. 579 (2):95-132. doi: 10.1016/j.gene.2015.12.061.
- 270 Hou, Y., Y. Cui, Z. Zhou, H. Liu, H. Zhang, Y. Ding, H. Nie, and H. L. Ji. 2019a. "Upregulation of the WNK4 Signaling Pathway
271 Inhibits Epithelial Sodium Channels of Mouse Tracheal Epithelial Cells After Influenza A Infection." *Front Pharmacol* no.
272 10:12. doi: 10.3389/fphar.2019.00012.
- 273 Hou, Yapeng, Yong Cui, Zhiyu Zhou, Hongfei Liu, Honglei Zhang, Yan Ding, Hongguang Nie, and Hong-Long Ji. 2019b.
274 "Upregulation of the WNK4 Signaling Pathway Inhibits Epithelial Sodium Channels of Mouse Tracheal Epithelial Cells
275 After Influenza A Infection." *Frontiers in pharmacology* no. 10:12. doi: 10.3389/fphar.2019.00012.
- 276 Huggins, D. J. 2020. "Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2." *J Mol Graph Model*
277 no. 100:107710. doi: 10.1016/j.jmgm.2020.107710.

- 278 Jaimes, J. A., N. M. Andre, J. S. Chappie, J. K. Millet, and G. R. Whittaker. 2020. "Phylogenetic Analysis and Structural Modeling
279 of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop." *J Mol Biol*
280 no. 432 (10):3309-3325. doi: 10.1016/j.jmb.2020.04.009.
- 281 Ji, H. L., X. F. Su, S. Kedar, J. Li, P. Barbry, P. R. Smith, S. Matalon, and D. J. Benos. 2006. "Delta-subunit confers novel biophysical
282 features to alpha beta gamma-human epithelial sodium channel (ENaC) via a physical interaction." *J Biol Chem* no. 281
283 (12):8233-41. doi: M512293200 [pii]
284 10.1074/jbc.M512293200.
- 285 Ji, H. L., R. Zhao, S. Matalon, and M. A. Matthay. 2020. "Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19
286 Susceptibility." *Physiol Rev* no. 100 (3):1065-1075. doi: 10.1152/physrev.00013.2020.
- 287 Kam, Y. W., Y. Okumura, H. Kido, L. F. Ng, R. Bruzzone, and R. Altmeyer. 2009a. "Cleavage of the SARS coronavirus spike
288 glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro." *PLoS One* no. 4
289 (11):e7870. doi: 10.1371/journal.pone.0007870.
- 290 Kam, Yiu-Wing, Yuushi Okumura, Hiroshi Kido, Lisa F. P. Ng, Roberto Bruzzone, and Ralf Altmeyer. 2009b. "Cleavage of the
291 SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in
292 vitro." *PloS one* no. 4 (11):e7870-e7870. doi: 10.1371/journal.pone.0007870.
- 293 Li, T., and Q. Zheng. 2020. "SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates."
294 no. 9 (1):2076-2090. doi: 10.1080/22221751.2020.1821583.
- 295 Love, M. I., W. Huber, and S. Anders. 2014. "Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2."
296 *Genome Biol* no. 15 (12):550. doi: 10.1186/s13059-014-0550-8.
- 297 Ly, A., C. Alessandri, E. Skripkina, A. Meffert, S. Clariot, Q. de Roux, O. Langeron, and N. Mongardon. 2020. "Rescue fibrinolysis
298 in suspected massive pulmonary embolism during SARS-CoV-2 pandemic." *Resuscitation* no. 152:86-88. doi:
299 10.1016/j.resuscitation.2020.05.020.
- 300 Matalon, S., R. Bartoszewski, and J. F. Collawn. 2015. "Role of epithelial sodium channels in the regulation of lung fluid
301 homeostasis." *Am J Physiol Lung Cell Mol Physiol* no. 309 (11):L1229-38. doi: 10.1152/ajplung.00319.2015.
- 302 Muhanna, D., S. R. Arnipalli, S. B. Kumar, and O. Ziouzenkova. 2020. "Osmotic Adaptation by Na(+)-Dependent Transporters and
303 ACE2: Correlation with Hemostatic Crisis in COVID-19." no. 8 (11). doi: 10.3390/biomedicines8110460.
- 304 Nie, H. G., T. Tucker, X. F. Su, T. Na, J. B. Peng, P. R. Smith, S. Idell, and H. L. Ji. 2009. "Expression and regulation of epithelial
305 Na⁺ channels by nucleotides in pleural mesothelial cells." *Am J Respir Cell Mol Biol* no. 40 (5):543-54.
- 306 Papamichalis, P., A. Papadogoulas, P. Katsiafylloudis, A. L. Skoura, M. Papamichalis, E. Neou, D. Papadopoulos, S. Karagiannis,
307 T. Zafeiridis, D. Babalis, and A. Komnos. 2020. "Combination of thrombolytic and immunosuppressive therapy for
308 coronavirus disease 2019: A case report." *Int J Infect Dis* no. 97:90-93. doi: 10.1016/j.ijid.2020.05.118.
- 309 Pollard, C. A., M. P. Morran, and A. L. Nestor-Kalinoski. 2020. "The COVID-19 Pandemic: A Global Health Crisis." *Physiol*
310 *Genomics*. doi: 10.1152/physiolgenomics.00089.2020.
- 311 Poor, H. D., C. E. Ventetuolo, T. Tolbert, G. Chun, G. Serrao, A. Zeidman, N. S. Dangayach, J. Olin, R. Kohli-Seth, and C. A. Powell.
312 2020. "COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial
313 dysfunction responsive to thrombolysis." *Clin Transl Med* no. 10 (2). doi: 10.1002/ctm2.44.
- 314 Roberts, K. A., L. Colley, T. A. Agbaedeng, G. M. Ellison-Hughes, and M. D. Ross. 2020. "Vascular Manifestations of COVID-19
315 - Thromboembolism and Microvascular Dysfunction." *Front Cardiovasc Med* no. 7:598400. doi:
316 10.3389/fcvm.2020.598400.
- 317 Sheng, S., M. D. Carattino, J. B. Bruns, R. P. Hughey, and T. R. Kleyman. 2006. "Furin cleavage activates the epithelial Na⁺ channel
318 by relieving Na⁺ self-inhibition." *Am J Physiol Renal Physiol* no. 290 (6):F1488-96. doi: 10.1152/ajprenal.00439.2005.
- 319 Sidarta-Oliveira, D., C. P. Jara, A. J. Ferruzzi, M. S. Skaf, W. H. Velandier, E. P. Araujo, and L. A. Velloso. 2020. "SARS-CoV-2
320 receptor is co-expressed with elements of the kinin-kallikrein, renin-angiotensin and coagulation systems in alveolar cells."
321 *Sci Rep* no. 10 (1):19522. doi: 10.1038/s41598-020-76488-2.
- 322 Smith, J. C., E. L. Sausville, V. Girish, M. L. Yuan, A. Vasudevan, K. M. John, and J. M. Sheltzer. 2020. "Cigarette Smoke Exposure
323 and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract." *Dev*
324 *Cell* no. 53 (5):514-529.e3. doi: 10.1016/j.devcel.2020.05.012.
- 325 Stuart, T., A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W. M. Mauck, 3rd, Y. Hao, M. Stoeckius, P. Smibert, and R. Satija.
326 2019. "Comprehensive Integration of Single-Cell Data." *Cell* no. 177 (7):1888-1902 e21. doi: 10.1016/j.cell.2019.05.031.

- 327 Sungnak, W., N. Huang, C. Becavin, M. Berg, R. Queen, M. Litvinukova, C. Talavera-Lopez, H. Maatz, D. Reichart, F. Sampaziotis,
328 K. B. Worlock, M. Yoshida, J. L. Barnes, and H. C. A. Lung Biological Network. 2020. "SARS-CoV-2 entry factors are
329 highly expressed in nasal epithelial cells together with innate immune genes." *Nat Med* no. 26 (5):681-687. doi:
330 10.1038/s41591-020-0868-6.
- 331 Thibodeau, P. H., and M. B. Butterworth. 2013. "Proteases, cystic fibrosis and the epithelial sodium channel (ENaC)." *Cell Tissue*
332 *Res* no. 351 (2):309-23. doi: 10.1007/s00441-012-1439-z.
- 333 Thierry, A. R. 2020. "Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting
334 COVID-19." *Physiol Rev* no. 100 (4):1597-1598. doi: 10.1152/physrev.00019.2020.
- 335 Vinayagam, S., and K. Sattu. 2020. "SARS-CoV-2 and coagulation disorders in different organs." *Life Sci* no. 260:118431. doi:
336 10.1016/j.lfs.2020.118431.
- 337 Wang, I. M., S. Stepaniants, Y. Boie, J. R. Mortimer, B. Kennedy, M. Elliott, S. Hayashi, L. Loy, S. Coulter, S. Cervino, J. Harris,
338 M. Thornton, R. Raubertas, C. Roberts, J. C. Hogg, M. Crackower, G. O'Neill, and P. D. Paré. 2008. "Gene expression
339 profiling in patients with chronic obstructive pulmonary disease and lung cancer." *Am J Respir Crit Care Med* no. 177
340 (4):402-11. doi: 10.1164/rccm.200703-390OC.
- 341 Wang, J., N. Hajizadeh, E. E. Moore, R. C. McIntyre, P. K. Moore, L. A. Veress, M. B. Yaffe, H. B. Moore, and C. D. Barrett. 2020.
342 "Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A
343 case series." no. 18 (7):1752-1755. doi: 10.1111/jth.14828.
- 344 Wang, Q., Y. Qiu, J. Y. Li, Z. J. Zhou, C. H. Liao, and X. Y. Ge. 2020. "A Unique Protease Cleavage Site Predicted in the Spike
345 Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility." *Virol Sin* no. 35
346 (3):337-339. doi: 10.1007/s12250-020-00212-7.
- 347 Wrapp, D., and N. Wang. 2020. "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation." no. 367 (6483):1260-
348 1263. doi: 10.1126/science.abb2507.
- 349 Xia, S., Q. Lan, S. Su, X. Wang, W. Xu, Z. Liu, Y. Zhu, Q. Wang, L. Lu, and S. Jiang. 2020. "The role of furin cleavage site in
350 SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin." *Signal Transduct Target*
351 *Ther* no. 5 (1):92. doi: 10.1038/s41392-020-0184-0.
- 352 Xu, J., X. Xu, L. Jiang, K. Dua, P. M. Hansbro, and G. Liu. 2020. "SARS-CoV-2 induces transcriptional signatures in human lung
353 epithelial cells that promote lung fibrosis." no. 21 (1):182. doi: 10.1186/s12931-020-01445-6.
- 354 Zhao, R., G. Ali, and H. G. Nie. 2020. "Plasmin improves blood-gas barrier function in oedematous lungs by cleaving epithelial
355 sodium channels." *Br J Pharmacol* no. 177 (13):3091-3106. doi: 10.1111/bph.15038.
- 356 Zhou, P., X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu, B. Li, C. L. Huang, H. D. Chen, J. Chen, Y. Luo,
357 H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X. Wang, X. S. Zheng, K. Zhao, Q. J. Chen, F. Deng, L. L. Liu, B.
358 Yan, F. X. Zhan, Y. Y. Wang, G. F. Xiao, and Z. L. Shi. 2020. "A pneumonia outbreak associated with a new coronavirus
359 of probable bat origin." *Nature* no. 579 (7798):270-273. doi: 10.1038/s41586-020-2012-7.
- 360

Figure 1.




Figure 1. Targeted molecular mimicry by SARS-CoV-2 of human γ ENaC and profiling ACE2-SCNN1G-PLAU/PLAT co-expression. (A) The cartoon showed the S-protein of SARS-CoV-2 (PDB ID: 6X2A), which was highlighted in green. The S1/S2 cleavage site required for the activation of SARS-CoV-2 was enlarged and highlighted in red. Furin/plasmin cleavage sites of common human viruses were shown in a box. (B) The cartoon represents the human γ ENaC protein (PDB ID: 6BQN), which was highlighted in green. Furin/plasmin cleavage site was enlarged and highlighted in red. The cleavage sites of γ ENaC in other species were shown in a box. (C) The single-cell transcriptomic co-expression of ACE2, SCNN1G (γ ENaC), and PLAU was summarized. The heatmap depicted the mean relative expression of each gene across the identified cell populations. The cell types were ranked based on decreasing expression of PLAU. The box highlighted the ACE2, SCNN1G (γ ENaC), and PLAU co-expressing cell types in the human respiratory system.

Figure 2.




Figure 2. Expression of proteases, γ ENaC, and ACE2 in the human respiratory system. Violin plots showing the expression level of PLAU, PLG, FURIN, TMPRSS2, and SCNN1G in nferX platform.

Figure 3.




Figure 3. Overall expression levels of proteases, ACE2, and SCNN1G in BALF bulk cells of COVID-19 patients. (A) Bubble plot of proteases, ACE2, and SCNN1G in BALFs of COVID-19 patients. The size of the dots indicated the proportion of cells in the respective cell type having a greater-than-zero expression of these genes, while the color indicated the mean expression of these genes. (B) The gene expression levels of proteases, ACE2, and SCNN1G from health controls (n = 4), moderate cases (n = 3) and severe cases (n = 6). *** $P_{adj} < 0.001$ (Wilcoxon test, P_{adj} was performed using Bonferroni correction).

Figure 4.




Figure 4. Transcription levels of proteases, ACE2, and SCNN1G in single epithelial cells of COVID-19 patients. (A) Bubble plot of SARS-CoV-2 receptor (ACE2) and proteases in BALFs epithelial cells of COVID-19 patients. The size of the dots indicated the proportion of cells in the respective cell type having a greater-than-zero expression of these genes, while the color indicated the mean expression of these genes. (B) The gene expression levels of selected proteases and ACE2 in epithelial cells from health controls (n = 4), moderate (n = 3), and severe cases (n = 6). (C) The gene expression levels of selected proteases and ACE2 in different epithelial cell types from health controls, moderate and severe cases. *** $P_{adj} < 0.001$ (Wilcoxon test, P_{adj} was performed using Bonferroni correction). AEC: alveolar epithelial cells.

Figure 5.




Figure 5. Changes of proteases, ACE2, and SCNN1G in respiratory cell lines after SARS-CoV-2 infection. Normal human bronchial epithelial (NHBE) and alveolar epithelial (A549, Calu-3) cells were infected with SARS-CoV-2 for 24 h (Infected), and control cells received culture medium only (Mock). The boxplot showed the changes of proteases (PLAU, FURIN, and TMPRSS), SCNN1G, and ACE2 in A549, Calu-3, and NHBE after SARS-CoV-2 infection. Differential genes were calculated by DESeq2, ****P*_{adj} < 0.001, **P*_{adj} < 0.05 (Wald test, *P*_{adj} was performed using Benjamini-Hochberg post-hoc test).

Figure 6.




Figure 6. SARS-CoV-2 infection hijacks the ENaC proteolytic network. In physiological conditions, the urokinase activates the plasminogen to plasmin, which will cleave the γ ENaC, leading to its activation. After infected by SARS-CoV-2, the PLAUI (urokinase) expression level is significantly upregulated, which may help other viruses' invasion by activating the plasminogen to cleave the S protein. The green solid line represents the urokinase, plasminogen, ENaC mRNA transcripts and activation by plasmin under physiological conditions. The red solid line represents the activation process under infection conditions, while the grey dotted line denotes the repression effects.